no longer marketing Hismanal (astemizole)

July 1999

Janssen is no longer marketing Hismanal (astemizole)......

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

controversy over the SPF ratings on sunscreens
Infectious Diseases restricting the use of Trovan (trovafloxacin)
Diabetes repaglinide, a new oral hypoglycemic for type 2 diabetes
Women's Health LOWER doses of estrogen to prevent osteoporosis
Women's Health Proclim Carousel, a convenient new device for women on HRT
Women's Health Many women are afraid that estrogen replacement therapy increases the risk of breast cancer
Women's Health HUGE study to compare tamoxifen and raloxifene for preventing breast cancer
Paxil (paroxetine) is now approved for social phobia
Wellbutrin SR for weight loss
now Pygeum africanum is the latest herb that's being promoted for benign prostatic hyperplasia
"andro" supplements DON'T build muscle
Dermatology using cimetidine (Tagamet, etc) for warts
new treatments for Restless Legs Syndrome (RLS)
Pediatrics Topamax (topiramate) is now approved for children as young as 2
Pediatrics more frequent liver monitoring for patients taking Cylert (pemoline)
Bipolar Disorder Neurontin (gabapentin) and Lamictal (lamotrigine) may be useful for treating bipolar disorder
Bipolar Disorder omega-3 fatty acids for bipolar disorder
Gastroenterology new warning for patients not to drink grapefruit juice while taking Prepulsid (cisapride)
Practice Cosopt eye drops for glaucoma
Practice no longer marketing Hismanal (astemizole)